Personalized Functional Profiling in Metastatic Gastrointestinal Cancer or Recurrent Glioblastoma Patients in Luxembourg.

Luxembourg Institute of Health57 enrolled

Overview

The investigators are developing a novel standardized and centralized approach named Integrated Personalized Functional Profiling (PFP) in Luxembourg. Based on recent improvements in cancer biopsy-derived 3D-culture technologies the PFP process will screen patient derived cells (PDCs) with FDA/EMA-approved drugs to generate personalized functional response profiles. The selected drug through PFP technology will provide personalized treatment recommendation for the patient. This pilot study will evaluate the clinical feasibility of setting-up an effective workflow as a first step. Outcomes from this study will be used subsequently to help plan the clinical validation of the implementation of PFP.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Oncology

Interventions

During this pilot study, the overall goal of the project is to establish an effective workflow between the patient, the PFP platform, the clinician and return to the patient. This includes collection of the biopsy or surgery piece and standardized processing, dissociation, drug profiling and issuing treatment recommendation to the clinician. In case the clinician follows this treatment recommendation, patient management and follow up will be performed according to standard of care.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with recurrent Glioblastoma (rGBM) or with metastatic gastrointestinal cancer (mGIC), i.e. adenocarcinoma (any grade) of stomach, liver, pancreas, small intestine, colon, rectum * The patient has received previous cancer treatment for mGIC or rGBM * Male or female ≥ 18 years * Life expectancy ≥ 12 weeks * Histologically or cytologically confirmed diagnosis for mGIC or recurrence of a glioblastoma, WHO grade IV * For women of childbearing potential, a negative pregnancy test documented prior to the screening visit is required * Signed Inform Consent Form before any study related procedure Exclusion Criteria: * For female patient, being pregnant, planning a pregnancy or breastfeeding * No fresh and viable tumor material available * Known active Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection * Uncontrolled medical conditions (i.e, diabetes mellitus, hypertension, etc), psychological, familial, sociological, or geographical conditions that do not allow compliance with the protocol; or unwillingness or inability to follow the procedures required in the protocol * In mGIC arm, patient with non-adenocarcinoma gastrointestinal cancer * Patient unable to understand and consent himself

Locations (2)

Centre hospitalier de Luxembourg

Luxembourg, Luxembourg, Luxembourg

Hôpitaux Robert Schmuan

Luxembourg, Luxembourg, Luxembourg

Outcomes

Primary Outcomes

Number of patients for which a treatment recommendation for their specific cancer can be formulated, based on PFP

Time frame: 4 weeks

Secondary Outcomes

Quantity of cells needed for the PFP analysis

Time frame: 4 weeks

Duration of the PFP process for one specific patient

Time frame: 4 weeks

Number of drugs recommended by using the PFP approach

Time frame: 4 weeks

Number of patients for which the treatment recommendation issued by PFP were followed by the investigator

Time frame: 4 weeks